SEC Info - Adaptimmune Therapeutics PLC

SEC Info℠

Home

Help

Please Sign In

Adaptimmune Therapeutics PLC – ‘8-K’ for 1/13/20

On: Monday, 1/13/20, at 7:09am ET · For: 1/13/20 · Accession #: 1104659-20-3216 · File #: 1-37368

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/13/20  Adaptimmune Therapeutics PLC      8-K:7,9     1/13/20   11:217K                                   Toppan Merrill/FA

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     15K 
 7: R1          Cover                                               HTML     49K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
10: XML         XBRL Instance -- tm201697d2_8k_htm                   XML     15K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- adap-20200113_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- adap-20200113_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- adap-20200113                         XSD     12K 
 6: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001104659-20-003216-xbrl      Zip     14K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0001621227 i false i 00-0000000 0001621227 2020-01-12 2020-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i January 13, 2020

i ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

i England and Wales		i 1-37368		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i 60 Jubilee Avenue, i Milton Park

i Abingdon, Oxfordshire i OX14 4RX

i United Kingdom

(Address of principal executive offices, including zip code)

( i 44) i 1235 430000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
i American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share		i ADAP		i The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On January 13, 2020, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing that its SPEAR T-cell platform has delivered initial responses in four solid tumor indications. The Company reported two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma, and two unconfirmed PRs – one in a patient with gastro-esophageal junction cancer and one in a patient with head and neck cancer. The press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit

99.1		Press release dated January 13, 2020

104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	ADAPTIMMUNE THERAPEUTICS PLC


Date: January 13, 2020	By:	/s/ *Margaret Henry*
		Name:	Margaret Henry
		Title:	Corporate Secretary

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/13/20	3, 4, 8-K
		List all Filings

↑Top

Filing Submission 0001104659-20-003216 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)